Episodes of major depression

Active Ingredient: Mirtazapine

Indication for Mirtazapine

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Treatment of episodes of major depression.

For this indication, competent medicine agencies globally authorize below treatments:

15-45 mg once daily

For:

Dosage regimens

Regimen A: Oral, 15 milligrams mirtazapine, once daily at the end of the day, over the duration of 2 to 4 weeks. Afterwards, oral, between 15 milligrams mirtazapine and 45 milligrams mirtazapine, once daily at the end of the day, over the duration of 6 months.

Regimen B: Oral, 30 milligrams mirtazapine, once daily at the end of the day, over the duration of 2 to 4 weeks. Afterwards, oral, between 30 milligrams mirtazapine and 45 milligrams mirtazapine, once daily at the end of the day, over the duration of 6 months.

Detailed description

Adults

The effective daily dose is usually between 15 and 45 mg; the starting dose is 15 or 30 mg.

Mirtazapine begins to exert its effect in general after 1-2 weeks of treatment. Treatment with an adequate dose should result in a positive response within 2-4 weeks. With an insufficient response, the dose can be increased up to the maximum dose. If there is no response within a further 2-4 weeks, then treatment should be stopped.

Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.

It is recommended to discontinue treatment with mirtazapine gradually to avoid withdrawal symptoms.

Elderly

The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response.

Dosage considerations

Mirtazapine has an elimination half-life of 20-40 hours and therefore is suitable for once daily administration. It should be taken preferably as a single night-time dose before going to bed. Mirtazapine may also be given in two divided doses (once in the morning and once at night-time, the higher dose should be taken at night).

Active ingredient

Mirtazapine

Mirtazapine is a centrally active presynaptic α2-antagonist, which increases central noradrenergic and serotonergic neurotransmission. The enhancement of serotonergic neurotransmission is specifically mediated via 5-HT1 receptors, because 5-HT2 and 5-HT3 receptors are blocked by mirtazapine. Both enantiomers of mirtazapine are presumed to contribute to the antidepressant activity, the S(+) enantiomer by blocking α2 and 5-HT2 receptors and the R(-) enantiomer by blocking 5-HT3 receptors.

Read more about Mirtazapine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.